CRP and Venous thrombosis: Anti-inflammatory therapy targeting the interleukin-1β with canakinumab in the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) study was associated with a significantly lower proportion of recurrent cardiovascular events independent of lipid levels in patients with acute myocardial infarction and CRP > 2 mg/L [27].